Eindhoven-based Salvia Bioelectronics has successfully closed a Series B funding round of 60 million dollars to bring its migraine therapy to market. This sizable investment will enable the startup to complete the clinical development phase and prepare for the commercial launch in the US, Europe and Australia...

Lees het volledige artikel bij Bits Chips.